临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 59277-89-3

Aciclovir (BW 248U)

中文名称:阿昔洛韦
CAS号:59277-89-3
分子式: C8H11N5O3 分子量: 225.20
产品形式: free base
研发状态: Not yet recruiting
研发用途: Healthy Volunteer
研究机构: International Bio service
研发日期: February 12 2024
研发阶段: Phase 1
Acyclovir (Acyclovir, Acycloguanosine, Zovirax, ACV, NSC 645011,BW 248U) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.

CAS: 59-23-4

D-Galactose

中文名称:半乳糖
CAS号:59-23-4
分子式: C6H12O6 分子量: 180.16
产品形式: free base
研发状态: Completed
研发用途: Noise Exposure; Sleep Disturbance; Sleep Hygiene; Metabolic Disturbance; Cognitive Change
研究机构: Göteborg University; University of Pennsylvania; University of Manitoba
研发日期: April 24 2022
研发阶段: Not Applicable
D-Galactose (D-Galactopyranose, D-(+)-Galactose) is an aldohexose that occurs naturally in the D-form in lactose, cerebrosides, gangliosides, and mucoproteins and is converted enzymatically into D-glucose for metabolism or polysaccharides for storage. It accelerates senescence in invertebrates and mammals and has been used as a model for aging.

CAS: 59-14-3

Bromodeoxyuridine (BrdU)

中文名称:5-溴-2'-脱氧尿苷
CAS号:59-14-3
分子式: C9H11BrN2O5 分子量: 307.10
产品形式: free base
研发状态: Recruiting
研发用途: Asthma
研究机构: University Hospital Bordeaux
研发日期: September 23 2020
研发阶段: --
Bromodeoxyuridine (BrdU, 5-Bromo-2'-deoxyuridine, BUdR) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.

CAS: 5908-99-6

Atropine sulfate monohydrate

中文名称:一水硫酸阿托品
CAS号:5908-99-6
分子式: 2(C17H23NO3).H2O.H2SO4 分子量: 694.83
产品形式: Sulfate monohydrate
研发状态: Not yet recruiting
研发用途: Opioid Use Unspecified; Anesthesia; Nociceptive Pain
研究机构: Ciusss de L''Est de l''Île de Montréal
研发日期: April 4 2024
研发阶段: Phase 4
Atropine sulfate monohydrate is a competitive antagonist for the muscarinic acetylcholine receptor, used to decrease the production of saliva and secretions of the airway prior to surgery.

CAS: 59-05-2

Methotrexate (CL-14377)

中文名称:甲氨蝶呤
CAS号:59-05-2
分子式: C20H22N8O5 分子量: 454.44
产品形式: free base
研发状态: Not yet recruiting
研发用途: Healthy Volunteers; Celiac Disease; Type 1 Diabetes
研究机构: Mozart Therapeutics Australia Pty Ltd
研发日期: Jun-24
研发阶段: Phase 1
Methotrexate (CL14377, MTX, NCI-C04671, Amethopterin, WR19039, abitrexate), analog of folic acid, is a nonspecific inhibitor of the dihydrofolate reductase(DHFR) of bacteria and cancerous cells as well as normal cells. It forms an inactive ternary complex with DHFR and NADPH. Methotrexate (MTX) induces apoptosis.

CAS: 590368-25-5

Upamostat (WX-671)

中文名称:4-[(2S)-3-[3-[(羟基氨基)亚氨基甲基]苯基]-1-氧代-2-[[[2,4,6-三(1-甲基乙基)苯基]磺酰基]氨基]丙基]-1-哌嗪甲酸乙酯
CAS号:590368-25-5
分子式: C32H47N5O6S 分子量: 629.81
产品形式: free base
研发状态: Recruiting
研发用途: SARS-CoV-2
研究机构: Henry M. Jackson Foundation for the Advancement of Military Medicine; Joint Program Executive Office Chemical Biological Radiological and Nuclear Defense Enabling Biotechnologies; RedHill Biopharma Limited; FHI Clinical Inc.
研发日期: January 29 2024
研发阶段: Phase 2
Upamostat (WX-671), a novel serine protease urokinase (uPA) inhibitor by inhibiting the urokinase-type plasminogen activator (uPA) system.